AN2 Therapeutics, Inc.
ANTX
$1.06
-$0.01-1.12%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -24.30% | 4.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 39.14% | -37.45% | |||
| Operating Income | -39.14% | 37.45% | |||
| Income Before Tax | -44.74% | 39.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -44.74% | 39.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -44.74% | 39.32% | |||
| EBIT | -39.14% | 37.45% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -44.21% | 39.54% | |||
| Normalized Basic EPS | -44.21% | 39.55% | |||
| EPS Diluted | -44.21% | 39.54% | |||
| Normalized Diluted EPS | -44.21% | 39.55% | |||
| Average Basic Shares Outstanding | 0.34% | 0.39% | |||
| Average Diluted Shares Outstanding | 0.34% | 0.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||